Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Exicure, Inc. (XCUR : NSDQ)

• Company Description    Exicure Inc. is a clinical-stage biotechnology company. It is engaged in developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid technology. Exicure Inc. is based in IL, United States. Number of Employees: 47

• Price / Volume Information    Yesterday's Closing Price: $0.12 Daily Weekly Monthly 20 Day Moving Average: 11,776,648 shares Shares Outstanding: 122.81 (millions) Market Capitalization: $14.86 (millions) Beta: 1.60 52 Week High: $1.98 52 Week Low: $0.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -29.81% -20.95% 12 Week -27.46% -20.24% Year To Date -40.13% -26.85%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2430 N. Halsted St. - Chicago,IL 60614 USA ph: 847-673-1700 fax: - ksharma@macbiocom.com http://www.exicuretx.com

• General Corporate Information    Officers Matthias Schroff - Chief Executive Officer; President and Director Elizabeth Garofalo - Chair of the Board of Directors Elias D. Papadimas - Chief Financial Officer Jeffrey L. Cleland - Director Bali Muralidhar - Director Peer Information Exicure, Inc. (CORR.) Exicure, Inc. (RSPI) Exicure, Inc. (CGXP) Exicure, Inc. (BGEN) Exicure, Inc. (GTBP) Exicure, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 30205M101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 122.81 Most Recent Split Date: (:1) Beta: 1.60 Market Capitalization: $14.86 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.14 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.59 Price/Cash Flow: - Price / Sales: 4.06 EPS Growth vs. Year Ago Period: 50.00% vs. Previous Quarter: 53.33% Sales Growth vs. Year Ago Period: 157.27% vs. Previous Quarter: 21.10% ROE 03/31/22 - -368.55 12/31/21 - -229.15 09/30/21 - -155.30 ROA 03/31/22 - -92.58 12/31/21 - -84.02 09/30/21 - -73.91 Current Ratio 03/31/22 - 1.37 12/31/21 - 1.28 09/30/21 - 2.92 Quick Ratio 03/31/22 - - 12/31/21 - 1.28 09/30/21 - 2.92 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -5,527.46 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 0.03 12/31/21 - 0.10 09/30/21 - 0.16 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 1.20 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 54.58

Powered by Zacks Investment Research ©